Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Dynavax Technologies Corporation (DVAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: DVAX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 7.45% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.60B USD | Price to earnings Ratio 64.35 | 1Y Target Price 24.75 |
Price to earnings Ratio 64.35 | 1Y Target Price 24.75 | ||
Volume (30-day avg) 2552362 | Beta 1.23 | 52 Weeks Range 9.74 - 14.63 | Updated Date 04/2/2025 |
52 Weeks Range 9.74 - 14.63 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 9.85% | Operating Margin (TTM) 0.8% |
Management Effectiveness
Return on Assets (TTM) 0.06% | Return on Equity (TTM) 4.48% |
Valuation
Trailing PE 64.35 | Forward PE 36.36 | Enterprise Value 1117523236 | Price to Sales(TTM) 5.76 |
Enterprise Value 1117523236 | Price to Sales(TTM) 5.76 | ||
Enterprise Value to Revenue 4.03 | Enterprise Value to EBITDA 24.45 | Shares Outstanding 124071000 | Shares Floating 99188424 |
Shares Outstanding 124071000 | Shares Floating 99188424 | ||
Percent Insiders 0.48 | Percent Institutions 107.53 |
Analyst Ratings
Rating 4.2 | Target Price 24.6 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Dynavax Technologies Corporation
Company Overview
History and Background
Dynavax Technologies Corporation was founded in 1996. It is a commercial-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Key milestones include the approval of HEPLISAV-B hepatitis B vaccine and the development of CpG 1018 adjuvant.
Core Business Areas
- Hepatitis B Vaccines: Focuses on the development, manufacture, and commercialization of HEPLISAV-B, a hepatitis B vaccine for adults.
- Adjuvant Technology: Develops and commercializes the CpG 1018 adjuvant, used in various vaccines to enhance immune response.
Leadership and Structure
Ryan Spencer is the Chief Executive Officer. The company has a typical corporate structure with departments focusing on research, development, manufacturing, commercialization, and finance.
Top Products and Market Share
Key Offerings
- HEPLISAV-B: HEPLISAV-B is a hepatitis B vaccine for adults. It is competing with Engerix-B and Recombivax HB. HEPLISAV-B has been gaining market share, capturing approximately 30% of the U.S. market. Competitors include GSK and Merck.
- CpG 1018 adjuvant: The CpG 1018 adjuvant is used in the Valnevau2019s IXCHIQ chikungunya vaccine and Clover Biopharmaceuticalsu2019 SCB-2019 COVID-19 vaccine. The adjuvant enhances the immune response to vaccines. Competitors include adjuvants from GSK and others.
Market Dynamics
Industry Overview
The vaccine market is experiencing growth driven by aging populations, increased awareness of preventative medicine, and advancements in vaccine technology.
Positioning
Dynavax is positioned as an innovative vaccine company, leveraging its HEPLISAV-B and CpG 1018 adjuvant to compete in the hepatitis B and adjuvant markets.
Total Addressable Market (TAM)
The total addressable market for hepatitis B vaccines is estimated to be several billion dollars globally. The total addressable market for vaccine adjuvants is also estimated to be several billion dollars globally. Dynavax's current market share positions it to capture a significant portion of these markets.
Upturn SWOT Analysis
Strengths
- HEPLISAV-Bu2019s superior efficacy and convenience
- CpG 1018 adjuvant platform
- Experienced management team
- Established manufacturing capabilities
Weaknesses
- Dependence on HEPLISAV-B sales
- Limited pipeline beyond HEPLISAV-B and adjuvant
- Competition from established pharmaceutical companies
- Relatively small sales force
Opportunities
- Expansion of HEPLISAV-B market share
- Development of new vaccines using CpG 1018 adjuvant
- Partnerships with other vaccine developers
- Geographic expansion
Threats
- Competition from established hepatitis B vaccines
- Patent expirations
- Regulatory challenges
- Potential for biosimilars
Competitors and Market Share
Key Competitors
- GSK (GSK)
- Merck (MRK)
- Valneva (VALN)
Competitive Landscape
Dynavax competes with larger pharmaceutical companies in the hepatitis B vaccine market. HEPLISAV-B's superior efficacy gives it a competitive advantage. In the adjuvant market, Dynavax is gaining traction through partnerships.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Dynavax experienced significant growth in revenue and profitability driven by increasing HEPLISAV-B sales and adjuvant revenue.
Future Projections: Analysts project continued revenue growth driven by market share gains for HEPLISAV-B and increased demand for CpG 1018 adjuvant.
Recent Initiatives: Recent initiatives include expanding the HEPLISAV-B sales force, pursuing new partnerships for CpG 1018 adjuvant, and exploring new vaccine candidates.
Summary
Dynavax is a growing biopharmaceutical company with a focus on vaccines and adjuvants. HEPLISAV-B sales drive significant revenue, and the CpG 1018 adjuvant has potential for further expansion. The company needs to diversify its pipeline and navigate competition to sustain long-term growth. Cashflow is healthy, while they need to increase new vaccine programs.
Similar Companies
INO
Inovio Pharmaceuticals Inc
INO
Inovio Pharmaceuticals Inc
MRNA
Moderna Inc
MRNA
Moderna Inc
VIR
Vir Biotechnology Inc
VIR
Vir Biotechnology Inc
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Market Research Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dynavax Technologies Corporation
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2004-02-19 | CEO & Director Mr. Ryan Spencer | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 405 | Website https://www.dynavax.com |
Full time employees 405 | Website https://www.dynavax.com | ||
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.